In this community, professionals share information regarding the clinical, programmatic and community-oriented aspects of early diagnosis, treatment and prevention of multi-drug-resistant tuberculosis (MDR-TB). Members also use this forum to promote universal access to quality care for MDR-TB.

Community moderators

Masoud Dara, MD
WHO Europe - EURO
Christopher Gilpin, PhD, MPH
World Health Organization - WHO

Recent community activity

Re : LTBI in MDR?


The consensus on the MDR TB preventive therapy as a public health concern is that there has been serious limitations in quality of evidence to draw any recommendations. However, the expert orientation is that decision should be guided by a comprehensive individual risk assessment that takes into account the risk ... read more

Updated: 25 Feb, 2018
Replies: 0


Joven Jebio Ongole replied

Until recently, WHO recommended INH on assumption that not all bacilli are resistant. This was dropped recently who WHO revised the way it gathers evidence and available evidences were not strong enough to make a recommendation. No specific guidelines are available and different centres practices combinations that include Rifampicin combined ... read more

Updated: 25 Feb, 2018
Reply: 1

Newborns of MDR patient

Masoud Dara, MD replied

Dear Betsy, Being a MDR-TB contact is not a contraindication to BCG vaccination. Unless the newborn has HIV infection or other contraindications, it is advisable to provide vaccine. If there are no signs for active TB and the tests have turned out negative and the clinician is sure that it ... read more

Updated: 25 Feb, 2018
Replies: 2

Culture negative TB treatment regimens in those with adverse drug reactions

Marlon L. Bayot replied

Hi, Andrew. One of the first things to consider in a culture negative and molecular negative case is to carefully review the history and physical examination result of the patient as there could have been some points missed during the assessment. Meanwhile, NTM infection could be a possibility as said ... read more

Updated: 23 Feb, 2018
Replies: 4

New community members

User Photo

Rajesh Rapally

Affiliated Organizations


Work Locations


User Photo

Jason Jacobus

Affiliated Organizations


Work Locations


User Photo

Tamas F Molnar

Prof. Dr. Tamas F Molnar PhD, DSc, FETCS, MA(hist)
d.o-b-(04.10.1953 Pécs, Hungary)
Roman Catholic

Hungarian academic thoracic surgeon, with a long list of research and publications on: thoracic empyema, chest trauma, pericardial fenestration, biotechnology in thoracic surgery and basic research in lung cancer.

Full professor at University of Pécs, Hungary, Head of St Sebastian Thoracic Surgery Unit:
Petz A Hospital, Győr, Hungary

Academy of Sciences Degre: 2012 Hungarian Academy of Sciences
Med Habil: 2008 University of Pécs, Hungary
European Board of Cardiothoracic Surgeons (FETCS): 1993
Candidate of Sciences (PhD): 1992 Hungarian Academy of Sciences
Specialist in Thoracic Surgery: 1986 (Hungarian Board of Medical Specialisations)
Specialist in Surgery : 1983 1986 (Hungarian Board of Medical Specialisations)
Doctor of Medicine (MD / Dr. med) 1979 (University of Pécs, Hungary
Maturation: 1972 (Gymnasium Tancsics / Kaposvar / Hungary)

Memberships: ESTS, UEMS (Thoracic Surgery Division)
Publications: No: 162 Impact Factor: 92.654 Independent Citations: 892

International trainings: Germany, UK (1989-2000) . Ex Consultant Thoracic Surgeon: BRI/ Bristol, UK. His main achievements are: Molnar-tray (systemic lympnode collection tool) pericardioperitoneal shunting and the Empyema Diamond. Special interest in history of chest surgery and medical humanities in thoracic fields. Founder of Thoracic Surgery Department at Pécs University (1994) and Thoracic Surgery Unit Petz A. Hospital,Győr (2012). Founder: Medical Humanities Unit / Operational Medicine Inst. University of Pécs, Hungary. President of Council of Thoracic Surgeons/Hungary.

Affiliated Organizations


Work Locations